MX366503B - Derivados de amatoxina. - Google Patents
Derivados de amatoxina.Info
- Publication number
- MX366503B MX366503B MX2015011583A MX2015011583A MX366503B MX 366503 B MX366503 B MX 366503B MX 2015011583 A MX2015011583 A MX 2015011583A MX 2015011583 A MX2015011583 A MX 2015011583A MX 366503 B MX366503 B MX 366503B
- Authority
- MX
- Mexico
- Prior art keywords
- relates
- amatoxin
- conjugates
- amatoxin derivatives
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Abstract
La presente invención se refiere a una amotoxina de la Fórmula I: caracterizada porque: R1 se selecciona de C=O, C=S, C=NR6 y CR7R8; R2 se selecciona de S=O, SO" y S; R3 se selecciona de NHR5 y OR5; R4 se selecciona de H, OR5, y OC1-6 alquilen-R5, cicloalquilen-R5, lhyeterocicloalquilen-R5, arilen-R5, y heteroarilen-R5; R7 y R8 se seleccionan independientemente de H, C1-6-alquilen -R5, cicloalquilen-R5, heterocicloalquilen-R5, arilen-R5, y heteroarilen-R5; en donde: (i) cada uno de R5 es H; (ii) uno de R5 es -Ln-X, en donde L es un enlazante, n se selecciona de 0 y 1, y X es una porción química que puede estar acoplada con una porción blanco, y es donde los restantes R5 son H; o (iii) uno de R5 es -Ln-X*-Y es una porción blanco, y X* es una Proción química que resulta del acoplamiento de X con una grupo funcional de Y, en donde los restantes R5 son H.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13001074.7A EP2774624A1 (en) | 2013-03-04 | 2013-03-04 | Amatoxin derivatives |
PCT/EP2014/000614 WO2014135282A1 (en) | 2013-03-04 | 2014-03-10 | Amatoxin derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015011583A MX2015011583A (es) | 2016-07-29 |
MX366503B true MX366503B (es) | 2019-07-11 |
Family
ID=47826817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011583A MX366503B (es) | 2013-03-04 | 2014-03-10 | Derivados de amatoxina. |
Country Status (19)
Country | Link |
---|---|
US (1) | US9982018B2 (es) |
EP (2) | EP2774624A1 (es) |
KR (1) | KR20160006162A (es) |
AR (1) | AR095019A1 (es) |
AU (1) | AU2014224928B2 (es) |
CA (1) | CA2903614C (es) |
DK (1) | DK2964264T3 (es) |
ES (1) | ES2652182T3 (es) |
HK (2) | HK1200312A1 (es) |
IL (1) | IL240863B (es) |
MX (1) | MX366503B (es) |
NO (1) | NO2964264T3 (es) |
NZ (1) | NZ710729A (es) |
RU (1) | RU2695370C2 (es) |
SG (1) | SG11201507089PA (es) |
TW (1) | TW201441248A (es) |
UA (1) | UA117364C2 (es) |
WO (1) | WO2014135282A1 (es) |
ZA (1) | ZA201505790B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2957354A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EA201790545A1 (ru) | 2014-09-12 | 2017-07-31 | Дженентек, Инк. | Антитела и иммуноконъюгаты против her2 |
US9751946B2 (en) | 2014-09-12 | 2017-09-05 | Genentech, Inc. | Anti-CLL-1 antibodies and immunoconjugates |
EP3215519A1 (en) | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
DK3265565T3 (da) * | 2015-03-04 | 2020-11-09 | Univ Texas | Fremgangsmåder til behandling af cancer, som har hemizygot tab af tp53 |
PL3268047T3 (pl) * | 2015-03-09 | 2024-03-18 | Heidelberg Pharma Research Gmbh | Nowe koniugaty amatoksyna-przeciwciało |
JP6632118B2 (ja) * | 2015-09-04 | 2020-01-15 | 学校法人 岩手医科大学 | 腫瘍の再発を抑制する医薬 |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
JP7022080B2 (ja) | 2016-05-27 | 2022-02-17 | ジェネンテック, インコーポレイテッド | 部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法 |
MA45408A (fr) | 2016-06-17 | 2019-04-24 | Magenta Therapeutics Inc | Compositions et procédés pour la déplétion des cellules cd117+ |
AU2017204139B2 (en) | 2016-06-17 | 2018-08-09 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
MX2019007604A (es) | 2016-12-23 | 2019-08-16 | Heidelberg Pharma Res Gmbh | Novedoso conjugado de amanitina. |
US10576161B2 (en) | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
EP3738608A4 (en) * | 2017-08-18 | 2021-12-08 | Sichuan Baili Pharm Co. Ltd | NON-NATURAL AMATOXIN TYPE ANTIBODY CONJUGATE |
AU2018355244A1 (en) | 2017-10-24 | 2020-04-09 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
CN111601616A (zh) | 2017-10-24 | 2020-08-28 | 美真达治疗公司 | 用于耗尽cd117+细胞的组合物和方法 |
WO2019197654A1 (en) * | 2018-04-13 | 2019-10-17 | Heidelberg Pharma Research Gmbh | Targeted amatoxin conjugate for the treatment of solid tumors |
MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
JP2022533430A (ja) * | 2019-05-23 | 2022-07-22 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 切断可能なリンカーを有する抗体薬物複合体 |
KR102092817B1 (ko) * | 2019-08-22 | 2020-03-24 | 한국화학연구원 | 아마톡신 유도체 및 이의 제조방법 |
CN111308100B (zh) * | 2020-04-13 | 2023-04-21 | 北京维德维康生物技术有限公司 | 一种检测β-鹅膏毒肽的酶联免疫试剂盒及其制备和应用 |
EP4213886A1 (en) | 2020-09-18 | 2023-07-26 | Araris Biotech AG | Transglutaminase conjugation method with amino acid-based linkers |
PE20231512A1 (es) | 2020-10-25 | 2023-09-26 | Araris Biotech Ag | Medios y metodos para producir conjugados de ligador-anticuerpo |
JP2024512478A (ja) * | 2021-03-19 | 2024-03-19 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bリンパ球特異的アマトキシン抗体コンジュゲート |
WO2023072934A1 (en) | 2021-10-25 | 2023-05-04 | Araris Biotech Ag | Methods for producing antibody-linker conjugates |
WO2023161291A1 (en) | 2022-02-22 | 2023-08-31 | Araris Biotech Ag | Peptide linkers comprising two or more payloads |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
EP2015782A4 (en) * | 2006-04-12 | 2010-04-07 | Crosslink Genetics Corp | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION |
ATE521366T1 (de) | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
KR20110140124A (ko) | 2009-04-08 | 2011-12-30 | 하인즈 파울스티히 | 암치료용 아미톡신-활성 표적 결합 부위 |
LT3192529T (lt) * | 2009-04-08 | 2020-06-25 | Faulstich, Heinz, Dr. | Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai |
EP2436398B1 (en) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
EP2497499A1 (en) * | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
-
2013
- 2013-03-04 EP EP13001074.7A patent/EP2774624A1/en not_active Withdrawn
-
2014
- 2014-03-04 TW TW103107305A patent/TW201441248A/zh unknown
- 2014-03-05 AR ARP140100717A patent/AR095019A1/es unknown
- 2014-03-10 SG SG11201507089PA patent/SG11201507089PA/en unknown
- 2014-03-10 US US14/769,970 patent/US9982018B2/en active Active
- 2014-03-10 NO NO14709884A patent/NO2964264T3/no unknown
- 2014-03-10 EP EP14709884.2A patent/EP2964264B1/en active Active
- 2014-03-10 WO PCT/EP2014/000614 patent/WO2014135282A1/en active Application Filing
- 2014-03-10 DK DK14709884.2T patent/DK2964264T3/en active
- 2014-03-10 ES ES14709884.2T patent/ES2652182T3/es active Active
- 2014-03-10 RU RU2015142093A patent/RU2695370C2/ru active
- 2014-03-10 MX MX2015011583A patent/MX366503B/es active IP Right Grant
- 2014-03-10 NZ NZ710729A patent/NZ710729A/en unknown
- 2014-03-10 CA CA2903614A patent/CA2903614C/en active Active
- 2014-03-10 KR KR1020157027378A patent/KR20160006162A/ko not_active Application Discontinuation
- 2014-03-10 AU AU2014224928A patent/AU2014224928B2/en active Active
- 2014-10-03 UA UAA201509530A patent/UA117364C2/uk unknown
- 2014-12-24 HK HK14113008.7A patent/HK1200312A1/xx unknown
-
2015
- 2015-08-12 ZA ZA2015/05790A patent/ZA201505790B/en unknown
- 2015-08-26 IL IL240863A patent/IL240863B/en active IP Right Grant
-
2016
- 2016-04-01 HK HK16103769.5A patent/HK1215795A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2774624A1 (en) | 2014-09-10 |
DK2964264T3 (en) | 2017-12-11 |
AU2014224928A1 (en) | 2015-09-10 |
NZ710729A (en) | 2019-05-31 |
EP2964264A1 (en) | 2016-01-13 |
CA2903614C (en) | 2021-07-06 |
WO2014135282A8 (en) | 2015-09-17 |
AR095019A1 (es) | 2015-09-16 |
US20160002298A1 (en) | 2016-01-07 |
RU2695370C2 (ru) | 2019-07-23 |
EP2964264B1 (en) | 2017-09-13 |
IL240863A0 (en) | 2015-10-29 |
IL240863B (en) | 2019-02-28 |
RU2015142093A (ru) | 2017-04-07 |
HK1215795A1 (zh) | 2016-09-15 |
MX2015011583A (es) | 2016-07-29 |
NO2964264T3 (es) | 2018-02-10 |
WO2014135282A1 (en) | 2014-09-12 |
UA117364C2 (uk) | 2018-07-25 |
SG11201507089PA (en) | 2015-10-29 |
US9982018B2 (en) | 2018-05-29 |
KR20160006162A (ko) | 2016-01-18 |
HK1200312A1 (en) | 2015-08-07 |
BR112015021838A2 (pt) | 2017-07-18 |
TW201441248A (zh) | 2014-11-01 |
ZA201505790B (en) | 2017-11-29 |
CA2903614A1 (en) | 2014-09-12 |
ES2652182T3 (es) | 2018-01-31 |
AU2014224928B2 (en) | 2017-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015011583A (es) | Derivados de amatoxina. | |
MX2013010286A (es) | Conjugados de amatoxinas con enlaces mejorados. | |
TN2015000396A1 (en) | Antibody drug conjugates | |
MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
PH12016501171A1 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
MX2013003452A (es) | Conjugados de amatoxina con enlazantes mejorados. | |
NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
MX2016007851A (es) | Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos. | |
MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
MX2021008334A (es) | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
GB201209613D0 (en) | New compounds | |
MX361218B (es) | Análogos de spliceostatina. | |
MX2016016515A (es) | Derivados de auristatina y conjugados de los mismos. | |
BR112019023246A8 (pt) | melhorias farmacocinéticas de quelatos bifuncionais e usos dos mesmos | |
WO2014197871A3 (en) | Antibody-drug conjugates, compositions and methods of use | |
MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
WO2014163714A3 (en) | Antibody drug conjugates | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
MX2016007825A (es) | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. | |
EA201491447A1 (ru) | Ендиины, их конъюгаты и способы их получения и применения | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |